Hemodynamic action of captopril in coronary patients with heart failure tolerant to nitroglycerin

Clinical Cardiology

Volumn 20, Issue 12, 1997, Pages 999-1004

  Störk, Thomas ^a   Eichstädt, Hermann ^b   Möckel, Martin ^a   Gareis, Ragnar ^a   Bodemann, Thomas ^c   Müller, Reinhold ^d  

^a Karl Olga Krankenhaus   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Klinik Nikolassee   (Germany)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

Captopril; Coronary heart disease; Heart failure; Nitrate tolerance; Nitroglycerin

Indexed keywords

CAPTOPRIL; GLYCERYL TRINITRATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HEADACHE; HEART INDEX; HEART WORK; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; MALE; ORAL DRUG ADMINISTRATION;

EID: 2642689672     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960201205     Document Type: Article

References (26)

1. Fung H-L, Bauer JA: Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489-499
2. May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, Hillis LD: In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-809
3. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804
4. Abrams J: A reappraisal of nitrate therapy. J Am Med Assoc 1988;259:396-401
5. Elkayam U: Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114:667-677
6. Münzel T, Kurz S, Heitzer T, Harrison DG: New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 1996;77: 24C-30C
7. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parnsley B: Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 1980;61:931-937
8. Chatterjee K, Rouleau J-L, Parmley WW: Captopril in congestive heart failure: Improved left ventricular function with decreased metabolic cost. Am Heart J 1982;104:1137-1146
9. Levine T, Franciosa J, Cohn J: Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 1980;62:35-41
10. Young JB: Reduction of ischemic events with angiotensin-converting enzyme inhibitors: Lessons and controversy emerging from recent clinical trials. Cardiovasc Drugs Ther 1995;9:89-102
11. Grossmann W: Clinical measurement of vascular resistance and assessment of vasodilator drugs. In Cardiac Catheterization and Angiography (Ed. Grossmann W), p. 135-142. Philadelphia: Lea & Febiger, 1986
12. Fleiss JL: Measuring agreement between two judges on the presence or absence of trait. Biometrics 1975;31:651-659
13. Abrams J: The role of nitrates in congestive heart failure. In Heart Failure - Mechanisms and Management (Eds. Lewis BL, Kimchi A), p. 256-261. Berlin-Heidelberg-New York: Springer, 1991
14. Armstrong PW, Armstrong JA, Marks GS: Pharmacogenetichemodynamic studies of intravenous nitroglycerin in congestive heart failure. Circulation 1980;62:160-166
15. Stork T, Möckel M, Stork S, Piske G, Danne O, Bodemann T, Müller R, Eichstädt H, Hochrein H: Hemodynamic response to molsidomine in coronary patients with heart failure tolerant to nitroglycerin. Z Kardiol 1993;82:293-301
16. Waldmann SA, Rapoport RM, Ginsburg R, Murad F: Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-3531
17. Axelsson KL, Andersson RG: Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Ear J Pharmacol 1983;88:77-79
18. Needleman P, Johnson EMJ: Mechanisms of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-715
19. Feelisch M, Keim M: Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 1991;180:286-293
20. Creager MA, Roddy M-A: Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24:499-505
21. Dakak N, Makhoul N, Flugelman MY, Merdler A, Shehadeh H, Schneeweiss A, Halon DA, Lewis BS: Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-613
22. Dupuis J, Lalonde G, Bichet D, Rouleau JL: Captopril does not prevent nitroglycerin tolerance in heart failure. Can J Cardiol 1990; 6:281-286
23. Pizzulli L, Hagendorff A, Zirbes M, Fehske W, Ewig S, Jung W, Lüderitz B: Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J 1996;131:342-349
24. Halon DA, Rosenfeld T, Hardoff R, Lewis BS: Advantage of combined therapy with captopril and nitrates in severe congestive heart failure. Isr J Med Sci 1988;24:664-670
25. Bussmann W-D, Feisinger K: Effect of captopril in nitrate tolerance. Dtsch med Wschr 1993;118:209-212
26. Münzel T, Bassenge E: Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;933:2052-2058